Pharmacies now have access to a POS-integrated lighted solution for streamlined prescription will call.
By Sandra Levy, Senior Editor, EnsembleIQ
Emporos, a pharmacy commerce system, and InterLink AI, creator of scripClip, a lighted pharmacy will-call system, have entered a strategic partnership. Pharmacies now have access to a POS-integrated lighted will-call solution for prescription, checkout and return to stock processes.
The partnership unlocks new value for pharmacies, including:
- The benefit of true integration – As the only POS with a fully integrated pick-to-light will-call solution, pharmacists no longer need to click between disparate applications. This enables the consolidation of vendors and creates greater safety and security.
- Search-and-retrieval time savings – With automatic light- and sound-enabled scripClip bags, clip-ons and beacons, pharmacy staff no longer need to sort through an alphabetized stack of scripts.
- Reduced errors – Avoid the risk of losing an Rx or dispensing the wrong medication to the wrong patient with built-in point-of-sale safety features that alert pharmacy staff if the prescriptions being bagged don’t match the patient.
[Read more: How retailers, pharmacy technology companies are redefining the modern healthcare experience]
- Return-to-stock time savings – Easily return prescription drugs to stock with automated, customizable triggers to free up shelf space, maximize inventory, avoid fees and minimize time spent on administrative tasks.
- Cost savings and unmatched ROI – By cutting back the time it takes to locate prescriptions, staff become more efficient, which leads to a reduction in costs and a boost in profits.
- Improved patient care – Less time spent searching for prescriptions and administrative work results in more time with patients, answering questions and ensuring they feel confident once they leave the pharmacy.
- Better work environment and staff retention – Pharmacists, technicians and support staff are able to focus on the more rewarding parts of their jobs, decreasing staff stress, burnout and turnover.
[Read more: Retail pharmacy in the age of AI]
Pharmacies that leverage this lighted will-call technology will receive the benefits of two solutions in one: The robust Emporos POS paired with scripClip will-call automation. scripClips work with new or existing will-call infrastructure, including refrigerators, locked cabinets, or other unique areas. Plus, the Emporos POS integrates with numerous pharmacy management systems, including McKesson EnterpriseRx, Epic Willow Ambulatory and Optum EPS.
“In a world where 74% of people abandon a physical line before it’s their turn and pharmacies rank second among places Americans spend the most time waiting, pharmacies of all kinds greatly benefit from lighted will call,” said Eric Kristensen, CEO of Emporos. “We shorten wait times in large hospitals, long-term care, community, chain and grocery store pharmacies by speeding up time-to-find prescriptions. These efficiencies lead to thousands of dollars saved every year, not to mention a boost in employee and patient satisfaction. But, most importantly, the Emporos Lighted Will-Call solution with scripClip provides the highest level of patient safety by ensuring the right medications are dispensed to the right patients.”
“Our partnership with Emporos reinforces the vision we share: to make the pharmacy experience more efficient and safer, for the health of pharmacies and their patients everywhere,” said Dan Gordon, president and CEO of InterLink AI. “We are thrilled to provide a solution that maximizes operational efficiency at the point of sale. More than one of every thousand prescriptions is correctly dispensed but ‘lost’ or mistakenly given to the wrong patient, resulting in HIPAA violations, double the fill time, wait time, and inventory cost, or, worst of all, patient harm and distrust. Whether it’s inside the pharmacy, curbside, or at a central fill or mailout facility, Emporos and scripClip are revolutionizing the way pharmacists are able to work, to support superior patient outcomes.”